-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2024
Empower your strategies with our Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2024 report and make more profitable business decisions. Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by the abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women ages 25 to 35. Most cases of cervical dysplasia are caused by human papillomavirus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts,...
-
Product Insights
Menopausal Disorders - Drugs In Development, 2024
Empower your strategies with our Menopausal Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Menopausal disorders encompass a range of symptoms and health issues that arise during and after menopause, a natural biological process marking the end of a woman's reproductive years. Common menopausal symptoms include hot flashes, night sweats, mood swings, and changes in sleep patterns. Hormonal fluctuations during this transition can also lead to conditions such as vaginal atrophy, affecting the genital tissues, and...
-
Product Insights
Female Sexual Dysfunction - Drugs In Development, 2024
Empower your strategies with our Female Sexual Dysfunction – Drugs In Development, 2024 report and make more profitable business decisions. Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen...
-
Product Insights
Polycystic Ovarian Syndrome - Drugs In Development, 2024
Empower your strategies with our Polycystic Ovarian Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Polycystic ovarian syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen, and polycystic ovaries. The main risk factor for PCOS is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy. The Polycystic Ovarian Syndrome drugs in development...
-
Product Insights
Vasomotor Symptoms of Menopause (Hot Flashes) - Drugs In Development, 2024
Empower your strategies with our Vasomotor Symptoms of Menopause (Hot Flashes) – Drugs In Development, 2024 report and make more profitable business decisions. Vasomotor symptoms of menopause include hot flashes or night sweats that result from the sudden opening of blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms can also be caused by some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections, and...
-
Product Insights
Premature Ovarian Failure - Drugs In Development, 2024
Empower your strategies with our Premature Ovarian Failure – Drugs In Development, 2024 report and make more profitable business decisions. Premature Ovarian Failure also known as primary ovarian insufficiency (POI) is a condition where a women's ovary tends to stop working in their 40s. It can also be defined as cessation of menses for more than 1 year before 40 years of age. It is not completely related to menopause, where women have fewer eggs. It can be autoimmune, or due...
-
Product Insights
Post Partum Depression (Maternal Depression / Postnatal Depression) - Drugs In Development, 2024
Empower your strategies with our Post Partum Depression (Maternal Depression / Postnatal Depression) – Drugs In Development, 2024 report and make more profitable business decisions. Post Partum Depression also known as maternal depression and postnatal depression is a medical condition occurs during the pregnancy or after giving the birth (post-partum). Most common condition is prevalent in 1 in 7 women. Many factors like anxiety during the trimester, psychological factors, social support, lifestyle changes, and hormonal changes can cause this condition. Most...
-
Product Insights
Premature Labor (Tocolysis) - Drugs In Development, 2024
Empower your strategies with our Premature Labor (Tocolysis) – Drugs In Development, 2024 report and make more profitable business decisions. Preterm labor or premature labor is defined as labor that begins before the completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding, and constant low, dull backache. Treatment includes corticosteroids and tocolytics. The Premature Labor (Tocolysis) drugs in development market research report provide comprehensive information on the...
-
Product Insights
Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2024
Empower your strategies with our Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses such as chronic renal failure, hyper-prolactinaemia, and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy. The Female Hypoactive Sexual Desire Disorder drugs in development market research report provide comprehensive information on...
-
Product Insights
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) - Drugs In Development, 2024
Empower your strategies with our Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Vaginal atrophy is the thinning, drying, and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning and urgency with urination, urinary tract infections, and urinary incontinence. Risk factors include smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.